baricitinib

Olumiant is the first and only FDA-approved JAK inhibitor for the treatment of COVID-19 in certain hospitalised adults requiring…

Arthritis drugs work by reducing inflammation caused by COVID-19 by blocking signals to the immune system that are causing it to…

More than 8,000 patients were administered baricitinib in addition to usual care, at random, or usual care alone, as part of the…

The extent to which these medicines, Baricitinib and Sotrovimab, will save lives depends on how widely available and affordable…

The trial -- 'India-UK RECOVERY (Randomised Evaluation of COVID-19 therapy)'-- will be a multi-centre, adaptive platform trial on…

Considering Bajaj Healthcare's manufacturing capabilities and strong in-house R&D team, we can produce Baricitinib at very…

BDR Pharma will be manufacturing and marketing the product under a royalty-free, limited and non-exclusive voluntary licence from…

Lilly had recently announced seven other voluntary license agreements with major drug manufacturers in India for the production of…

Lilly had also signed voluntary license agreements with Cipla, Lupin, Sun Pharma, Dr Reddy’s, MSN Labs and Torrent Pharma

On May 10, Lilly had also announced the signing of three Voluntary License Agreements with Cipla, Lupin and Sun Pharma Industries